No Abstract BioWorld International CorrespondentOncodesign SA is heading up a cancer biomarker consortium that has secured €10 million (US$14.1 million) from the French innovation agency OSEO to develop a new generation of tumor-specific radiotracers. Read More
Almost a full year after Pfizer Inc. decided to discontinue development of PF-03187207, it finally handed the compound back to its erstwhile partner, NiCox SA, and has withdrawn from its strategic alliance in ophthalmology with the company. (BioWorld International) Read More
